Key terms
About AIM
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AIM news
Apr 19
5:03pm ET
AIM ImmunoTech files to sell 9.98M shares of common stock for holders
Apr 18
8:48am ET
AIM ImmunoTech announces reslease of CEO Corner segment
Apr 15
9:05am ET
AIM ImmunoTech appoints Lapp as a consulting Medical Officer
Apr 03
3:05pm ET
Ampligen’s Prospects in Post-COVID Fatigue and Cancer Treatment: A Strong Buy Recommendation
Apr 02
2:00am ET
Navigating the Future: Aim Immunotech’s Challenge Against Rapid Tech Evolution in Pharma
Mar 25
9:18am ET
AIM ImmunoTech announces publication of findings from Ampligen study
Mar 21
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Mar 07
8:45am ET
AIM ImmunoTech launches CEO Corner platform
Feb 29
8:48am ET
AIM ImmunoTech outlines recent progress across development pipeline
Feb 20
4:44pm ET
AIM ImmunoTech Secures $2.5 Million Funding and Debt Terms
Feb 15
1:45pm ET
Buy Rating Affirmed for AIM ImmunoTech Amidst Promising Trials and Product Pipeline Developments
Feb 14
8:57am ET
AIM ImmunoTech announces first subject dosed in Netherlands for Ampligen study
Feb 10
4:20am ET
AIM ImmunoTech Touts Ampligen’s Post-COVID Study Success
Feb 08
8:53am ET
AIM ImmunoTech reports topline results from Phase 2 study of Ampligen
Jan 26
4:52am ET
AIM ImmunoTech Discloses Q1 Pancreatic Cancer Program Update
Jan 24
9:12am ET
AIM ImmunoTech receives Erasmus MC Ethics Board authorization
Jan 22
8:57am ET
AIM ImmunoTech enrolls first subject in Phase 1b/2 study of Ampligen
No recent press releases are available for AIM
AIM Financials
Key terms
Ad Feedback
AIM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AIM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
